{
    "clinical_study": {
        "@rank": "142905", 
        "acronym": "Mod2EpiCF", 
        "arm_group": [
            {
                "arm_group_label": "Cystic Fibrosis patients (CF)", 
                "arm_group_type": "Experimental", 
                "description": "Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects"
            }, 
            {
                "arm_group_label": "Control subjects (non CF)", 
                "arm_group_type": "Other", 
                "description": "Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects"
            }
        ], 
        "brief_summary": {
            "textblock": "Epigenetic modifiers has been showed to rescue F508del-CFTR channel to apical membrane of\n      epithelial cell lines. In this study, the investigators evaluate epigenetic modifiers\n      effects firstly on CFTR rescue, then on secretion and synthesis of inflammatory factors\n      (IL-8, LXA4 and SCGB1A1) and mucines (MUC5AC and MUC5B) in a dynamic epithelium model using\n      an air-liquide interface culture of nasals cells from CF patients or controls."
        }, 
        "brief_title": "Action of Epigenetic Modifiers in Cystic Fibrosis Treatment: ex Vivo Model of Nasal Epithelium of CF Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cystic Fibrosis", 
            "Healthy Subjects"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "General inclusion criteria :\n\n          -  informed consent\n\n          -  benefit from disease insurance regimen\n\n          -  men and women\n\n        Inclusion Criteria for CF patients\n\n          -  2 severe CF mutations\n\n          -  age superior or equal to 12\n\n        Inclusion Criteria for controls :\n\n          -  age superior or equal to 18\n\n          -  no smoker (for 5 years)\n\n        General exclusion criteria :\n\n          -  participation to an other interventionnal study\n\n          -  subject in exclusion period\n\n          -  law protected subject\n\n          -  pregnant and breast fooding\n\n        Specific Exclusion Criteria:\n\n          -  Xylocaine hypersensibility\n\n          -  Porphyria\n\n          -  severe hepatic failure\n\n          -  Epilepsy\n\n          -  Severe cardiac failure\n\n          -  local anesthesic contra indication\n\n        Specific Control subject Exclusion Criteria:\n\n          -  respiratory disease\n\n          -  cystic fibrosis\n\n          -  acute infection < 6 weeks\n\n          -  on treatment\n\n          -  antibiotic treatment < 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01883284", 
            "org_study_id": "8870"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cystic Fibrosis patients (CF)", 
                "Control subjects (non CF)"
            ], 
            "description": "Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.", 
            "intervention_name": "Tests in vitro after sampling nasal cells of CF patients or controls", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cystic Fibrosis", 
            "nasal epithelia", 
            "mucins"
        ], 
        "lastchanged_date": "June 20, 2013", 
        "location": {
            "contact": {
                "email": "r-chiron@chu-montpellier.fr", 
                "last_name": "Rapha\u00ebl CHIRON, MD", 
                "phone": "(+33)467336089"
            }, 
            "contact_backup": {
                "email": "anne.bergougnoux@inserm.Fr", 
                "last_name": "Anne BERGOUGNOUX, PhD", 
                "phone": "(+33)411759879"
            }, 
            "facility": {
                "address": {
                    "city": "Montpellier", 
                    "country": "France", 
                    "zip": "34295"
                }, 
                "name": "Respiratory Diseases Department"
            }, 
            "investigator": [
                {
                    "last_name": "Rapha\u00ebl RC CHIRON, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Arnaud AB BOURDIN, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Action of Epigenetic Modifiers in Cystic Fibrosis Treatment: ex Vivo Model of Nasal Epithelium of CF Patients", 
        "overall_contact": {
            "email": "nicolas.molinari@inserm.fr", 
            "last_name": "Nicolas MOLINARI, PhD", 
            "phone": "(+33)467338979"
        }, 
        "overall_official": {
            "affiliation": "Arnaud de Villeneuve CHU Montpellier", 
            "last_name": "Rapha\u00ebl RC CHIRON, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mature CFTR protein percentage variation after in vitro epigenetics modifiers treatment", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01883284"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pro-inflammatory cytokines number variations after epigenetic modifiers treatment", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Anti-inflammatory cytokines number variations after epigenetic modifiers treatment", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Mucin composition variations after epigenetic modifiers treatment", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "University Hospital, Montpellier", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Montpellier", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}